Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 10:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 989 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diseases of the Musculoskeletal System and Connective Tissue Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

RHYTHM (Formerly Escape II Myocardium)

NCT01548768
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
TNF inhibitors, DMARDs
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 27, 2020 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 2 Interventional

Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops

NCT00001731
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Cyclosporin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Pediatric Arthritis Study of Certolizumab Pegol

NCT01550003
View directory record Official record
Conditions
Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
Interventions
Certolizumab Pegol (CZP)
Drug
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
2 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Early Phase 1 Interventional

Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases

NCT02925351
View directory record Official record
Conditions
Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Takayasu Arteritis
Interventions
Computed Tomography, Fluorine F 18 Clofarabine, Positron Emission Tomography
Procedure · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 4, 2020 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Vagus Nerve Stimulator in Patients With Rheumatoid Arthritis (RA)

NCT03437473
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
SetPoint Medical Neurostimulation of the Cholinergic Anti-inflammatory Pathway System
Device
Lead sponsor
SetPoint Medical Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
4
States / cities
Aventura, Florida • Zephyrhills, Florida • Great Neck, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2018 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome

NCT02291029
View directory record Official record
Conditions
Primary Sjögren's Syndrome
Interventions
CFZ533 active - Cohort 1, CFZ533 placebo- Cohort 1, CFZ533 active - Cohort 2, CFZ533 placebo - Cohort 2, CFZ533 active - Cohort 3
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • Mineola, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 1 Interventional

A Study to Investigate How JNJ-39758979 May Affect the Plasma Levels of Methotrexate in Rheumatoid Arthritis Participants

NCT01442545
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
JNJ-39758979 / MTX
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
3
States / cities
Daytona Beach, Florida • Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 4 Interventional

Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer

NCT00082277
View directory record Official record
Conditions
Breast Cancer
Interventions
Anastrozole, Risedronate Sodium
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
55 Years and older · Female only
Enrollment
237 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
8
States / cities
Palm Springs, California • Jacksonville, Florida • New Orleans, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 2 Interventional

Phase 2 Efficacy Trial of OLT1177 Gel in Subjects With Moderate to Severe Pain Associated With OA of the Knee

NCT01768975
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
OLT1177 Gel, Placebo gel
Drug · Other
Lead sponsor
Olatec Therapeutics, Inc.
Industry
Eligibility
35 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
DeLand, Florida • South Miami, Florida • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 6, 2014 · Synced Oct 28, 2026, 10:48 AM EDT
Not listed Not applicable Interventional

The Impact of a Seated Compact Elliptical Trainer on Individuals With Knee OA

NCT05857605
View directory record Official record
Conditions
Osteoarthritis, Knee Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions
Exercise for Knee Osteoarthritis, Compact seated elliptical exercise machine- Cubii JR-1
Other · Device
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
50 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sonographic Features of Normal Soft Tissues of the Feet

NCT00719004
View directory record Official record
Conditions
Foot Disease, Healthy
Interventions
Ultrasound of the foot
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 7, 2016 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 3 Interventional

Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis

NCT00352625
View directory record Official record
Conditions
Tendonitis, Bursitis
Interventions
Ketoprofen Topical Patch 20%
Drug
Lead sponsor
Alkemira SA
Industry
Eligibility
18 Years and older
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)

NCT02319759
View directory record Official record
Conditions
Psoriatic Arthritis
Interventions
Guselkumab, Ustekinumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Huntsville, Alabama • Trumbull, Connecticut • Clearwater, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 28, 2026, 10:48 AM EDT
Completed No phase listed Observational

The Effect of Guided Care With Vectra Compared to Treatment as Usual in Patients With Rheumatoid Arthritis

NCT03631225
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Vectra
Diagnostic Test
Lead sponsor
Sequenom, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
30
States / cities
La Mesa, California • Murrieta, California • Orange, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 28, 2026, 10:48 AM EDT
Completed No phase listed Observational

Study of Psoriatic Arthritis

NCT00001420
View directory record Official record
Conditions
Psoriasis, Psoriatic Arthritis
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
Not listed
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Filgotinib in Combination With Methotrexate in Adults With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

NCT02889796
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Filgotinib, Placebo to match filgotinib, Adalimumab, Placebo to match adalimumab, MTX
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
1,759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
48
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Not applicable Interventional

Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project

NCT02440906
View directory record Official record
Conditions
Chronic Mental Illness, Chronic Physical Illness
Interventions
Patient-Directed Wellness Account, Health Navigator
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
21 Years to 55 Years
Enrollment
1,663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2017 · Synced Oct 28, 2026, 10:48 AM EDT
Completed No phase listed Observational

Prospective Study Measuring Clinical Outcomes of Knee Arthroplasty Using the VERASENSE™ Knee System

NCT01469299
View directory record Official record
Conditions
Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Post-traumatic Arthritis
Interventions
Not listed
Lead sponsor
Orthosensor, Inc.
Industry
Eligibility
50 Years and older
Enrollment
285 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
8
States / cities
St. Helena, California • Fort Lauderdale, Florida • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

NCT03747939
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Apremilast (CC-10004), Apremilast (CC-10004) Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Mesa, Arizona • Covina, California • Encino, California + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 3 Interventional

GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids

NCT00082511
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
Prasterone (GL701)
Drug
Lead sponsor
Genelabs Technologies
Industry
Eligibility
18 Years and older · Female only
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
21
States / cities
Tucson, Arizona • Los Angeles, California • Rancho Mirage, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2008 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Early Phase 1 Interventional

Human Factors Study of Methotrexate Prefilled Pen (50 mg/mL) in Patients With Juvenile Idiopathic Arthritis

NCT02052167
View directory record Official record
Conditions
Juvenile Idiopathic Arthritis
Interventions
methotrexate prefilled pen
Device
Lead sponsor
medac GmbH
Industry
Eligibility
2 Years to 20 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 28, 2026, 10:48 AM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

NCT00634933
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
TRU-015, Methylprednisolone, Prednisone
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
29
States / cities
Birmingham, Alabama • Paradise Valley, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 1 Interventional

A Study of RO5310074 in Patients With Psoriatic Arthritis

NCT01199809
View directory record Official record
Conditions
Arthritis, Psoriatic
Interventions
Placebo, RO5310074
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
6
States / cities
Anniston, Alabama • Los Angeles, California • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Oct 28, 2026, 10:48 AM EDT
Completed Phase 3 Interventional Results available

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

NCT00960440
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CP-690,550, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
36
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced Oct 28, 2026, 10:48 AM EDT